52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B.

MLA

Piratvisuth, Teerha, et al. “52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B.” PLoS ONE, vol. 8, no. 2, Feb. 2013, pp. 1–8. EBSCOhost, https://doi.org/10.1371/journal.pone.0054279.

APA

Piratvisuth, T., Komolmit, P., Tanwandee, T., Sukeepaisarnjaroen, W., Chan, H. L. Y., Pessôa, M. G., Fassio, E., Ono, S. K., Bessone, F., Daruich, J., Zeuzem, S., Cheinquer, H., Pathan, R., Dong, Y., & Trylesinski, A. (2013). 52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B. PLoS ONE, 8(2), 1–8. https://doi.org/10.1371/journal.pone.0054279

Chicago

Piratvisuth, Teerha, Piyawat Komolmit, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Henry L. Y. Chan, Mário G. Pessôa, Eduardo Fassio, et al. 2013. “52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B.” PLoS ONE 8 (2): 1–8. doi:10.1371/journal.pone.0054279.